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Abstract
Rationale Magnetic resonance spectroscopy (MRS) is an ac-
ceptable non-invasive means of studying brain neurochemis-
try in depression. Previous studies in depressed patients have
focused on measurement of the amino acid neurotransmitters,
γ-aminobutyric acid (GABA) and glutamate.
Objectives The aim of this study is to useMRS in conjunction
with the ultrashort echo time ‘SPECIAL’ technique to mea-
sure cortical levels of GABA, glutamate and glutathione
(GSH) levels in unmedicated patients with major depression.
We also examined the effect of 6-week treatment with the
selective serotonin re-uptake inhibitor, escitalopram.
Methods We studied patients with DSM-IV major depression
and healthy age-matched controls using proton MRS. GABA,
glutamate and GSH were measured relative to creatine in a
voxel placed in occipital cortex.
Results There was no difference in GABA or glutamate levels
between depressed participants and controls; however, de-
pressed patients had lower GSH levels. Six-week escitalopram
treatment, which resulted in significant clinical responses in
some patients, did not alter concentrations of GABA, gluta-
mate or GSH.
Conclusions The sources of variability of GABA and gluta-
mate measures in different studies of depressed patients re-
quire further study. Our results suggest that concomitant treat-
ment with selective serotonin re-uptake inhibitors (SSRIs) is
unlikely to be an important confounding factor. If lowered
GSH levels can be confirmed, theymay represent the presence
of oxidative stress in some depressed patients.
Keywords Depression . GABA .Glutamate . Glutathione .
SSRIs .Magnetic resonance spectroscopy (MRS)
Introduction
Magnetic resonance spectroscopy (MRS) provides an accept-
able and non-invasive means of assessing aspects of brain
neurochemistry in depressed patients in vivo. Particular atten-
tion has focused on levels of the amino acid neurotransmitters,
glutamate and γ-aminobutyric acid (GABA) because of their
postulated role in the pathophysiology of depression (Taylor
et al. 2003; Sanacora et al. 2008; Sanacora 2010). Findings to
date in MRS studies in patients with major depression have
not been particularly consistent, probably related to methodo-
logical factors and likely patient heterogeneity. However, a
recent meta-analysis of studies of glutamate in depressed
patients indicated that MRS glutamate was likely to be de-
creased in acute depression, particularly in anterior brain
regions (Yüksel and Öngür 2010). GABA concentrations are
also reported to be lowered in depression, particularly in
occipital cortex where GABA is easier to measure with cur-
rent MRS methodology (Sanacora et al. 1999, 2004; Hasler
et al. 2007).
Glutathione (GSH) is a major endogenous free radical
scavenger, and its reduction can increase vulnerability to
cellular oxidative stress (Berk et al. 2008). There is evidence
that patients with depression have decreased antioxidant ca-
pacity in plasma as shown by lowered levels of glutathione
peroxidase (GPX) (Maes et al. 2011). Also a post-mortem
study of prefrontal cortex in brain tissue, derived from the
Stanley Foundation Consortium, found lowered levels of both
GSH and GPX in patients diagnosed with major depression
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(Gawryluk et al. 2011). A recent MRS study reported
lower levels of GSH in occipital cortex in both patients
with major depression and those with chronic fatigue syn-
drome (Shungu et al. 2012).
In conjunction with proton MRS, the short echo time
‘SPECIAL’ technique (Mekle et al. 2009; Near et al. 2013)
enables simultaneous detection of GSH as well as several
other neurometabolites, including GABA, glutamate and glu-
tamine in a single acquisition, without the need for spectral
editing. The primary aim of this study was to compare GABA,
glutamate, glutamine and GSH levels in occipital cortex
(OCC), in unmedicated patients with major depression and
healthy controls. The secondary aim was to assess the effects
of 6-week treatment with the selective serotonin re-uptake
inhibitor (SSRI), escitalopram, on glutamate, glutamine,
GABA and GSH. This investigation was part of a combined
study that also looked at the ability of escitalopram to change
the neural substrate of emotional processing measured by
functional magnetic resonance imaging (fMRI). Results from
this part of the study will be reported separately.
Methods
Participants, mood ratings and antidepressant treatment
Participants were recruited through mental health clinics and
advertising in local newspapers. Before enrolment to the study
volunteers were assessed for current and past Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition Text
Revision (DSM-IV)-TR depressive disorder and other Axis 1
diagnoses by the Structured Clinical Interview for DSM-IV
Axis I Disorders Schedule (SCID-I) (First et al. 1997).
The final participant sample included 39 patients with
major depression and 31 healthy controls with a similar age
and gender distribution. Exclusion criteria from the study
were as follows: for depressed patients—suffering from psy-
chosis or substance dependence as defined by DSM-IV, being
at clinically significant risk of suicidal behaviour, having
contraindications to escitalopram treatment or being treated
with psychiatric medication less than 3 weeks before the
beginning of the study; for healthy volunteers—current or
past history of Axis I disorder as defined by DSM-IV; and
for both groups —major somatic or neurological disorders,
pregnancy or breast-feeding, contraindications to MRS imag-
ing. The study was approved by Oxford Research Ethics
Committee in accordance with the Helsinki Declaration of
1964. All participants gave written informed consent
prior to their inclusion in the study. Participants were reim-
bursed for their time.
Mood ratings were measured using the Hamilton Rating
Scale for depression (HAM-D) (Hamilton 1960) and the Beck
Depression Inventory (BDI) (Beck et al. 1961), while anxiety
ratings were scored using the Spielberger’s State-Trait
Anxiety Inventory (Spielberger et al. 1993). Ratings were
carried out immediately prior to MRS scanning. After the first
MRS scan, depressed patients were treated for 6 weeks with
escitalopram, 10 mg daily, following which MRS scanning
was carried out again.
MRS methodology
Scanning was performed on a 3T Siemens TIM Trio scanner
(Erlangen, Germany) with a body coil transmitter and a 32-
channel receive head array. Data were acquired from a 20×
25×20 mm voxel located in the occipital cortex (OCC). The
voxel was positioned manually by reference to an axial T1-
weighted gradient echo image.
SPECIAL data with water suppression were acquired (TE
8.5 s, 3,200 ms, 16-step phase cycle, 128 averages for the
occipital voxel). Six outer volume suppression slabs were
applied (one on each side of the cubic voxel) to suppress signals
originating from outside the volume of interest and to minimise
motion-related image-selected in vivo spectroscopy (ISIS) sub-
traction artefacts. For all spectra, a semi-automated processing
chain was applied, which involved the removal of motion-
corrupted averages and frequency and phase drift corrections
prior to signal averaging. Motion-corrupted averages were
always discarded in combination with the corresponding ISIS
subtraction pair; however, to prevent signal-to-noise ratio
(SNR) loss, the remainder of the 16-step phase encode cycle
was not discarded. Following spectral processing, SPECIAL
data were analysed with LCModel version 6.2-2B (Provencher
1993) using a basis set that consisted of 21 simulated metabo-
lite basis spectra. Basis spectra were generated using an in-
house, MATLAB (Natick MA, USA) based implementation of
the density matrix formalism to simulate the effect of the
SPECIAL pulse sequence on each of the 21 metabolite spin
systems studied. All metabolite concentrations were calculated
in reference to total creatine (creatine + phosphocreatine).
Quantification reliability and spectral quality were assessed
using Cramer-Rao lower bounds (CRLB), spectral linewidth
and SNR, and strict quality limits were enforced. Specifically,
concentration estimates with CRLB >20 % were rejected as
unreliable and all spectra with linewidth greater than 8 Hz (one
spectrum) or SNR less than 50 (one spectrum) were removed
from further analysis. SNR was defined as the maximum (real)
signal intensity between 0.2 and 4.2 ppm divided by the
standard deviation of the fit residual over the same frequency
range. Linewidth was defined as the full width at half maxi-
mum of the fitted peaks. T1-weighted structural images were of
whole brain and were acquired with 1-mm3 voxel resolution,
and FSL FASTwas used to segment the structural brain images
into grey matter, white matter and CSF, to allow estimation of
voxel composition (for more information about the accuracy
and reliability of SPECIAL in conjunction with the LCModel
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in the measurement of GABA concentrations, see Near et al.
(2013)).
Group differences were analysed using unpaired t tests or
MANOVA in SPPS v.20 (SPSS Inc., Chicago, IL, USA).
Effects of escitalopram treatment were compared by paired t




There was no significant difference in age and gender ratio
between patients and controls. The ratings on the HAM-D
score showed that the majority of the patients were moderately
depressed. Tenmet DSM-IV criteria for major depressionwith
melancholia; three patients had a history of panic attacks; and
one had comorbid generalised anxiety disorder. The mean
antidepressant free period for patients with recurrent depres-
sion was 111 weeks (range 12–468); however, 22 patients had
never received treatment with antidepressants. Two patients
were treatment-resistant during the current episode, each hav-
ing received three courses of antidepressants (one, two
courses of SSRIs and one course of mirtazapine and the other,
two courses of SSRIs and one course of lofepramine).
Demographic data are presented in Table 1.
MRS analysis
Representative spectra and the corresponding voxel place-
ment are shown in Fig. 1 Also shown are the spectral fits as
well as the residuals (data fit), where the flatness of the
residuals can serve as an indicator of the goodness of fit.
Due to technical limitations (see above) we excluded six
patients and four healthy controls from the between-group
analysis. Within-subject analysis for the effect of escitalopram
treatment was carried out in 27 patients for whom valid data
from baseline and 6-week scans were available.
The two groups did not differ significantly in terms of
voxel composition in regards to white matter and cerebrospi-
nal fluid content; however, grey matter content was signifi-
cantly lower in the patient group (Table 1), and grey matter
content was therefore entered as a covariate into the compar-
ison of depressed patients and controls. There were no signif-
icant differences in any measures of voxel content when the
pre-treatment and treatment scans of the depressed patients
were compared (data not shown).
The MANOVA showed that depressed patients had lower
GSH levels (F=5.10, p=0.028) (Fig. 1), but depressed patients
and controls did not differ in concentration of any other metab-
olites (GABA, glutamine, glutamate; all p values, p>0.3)
(Fig. 2, Table 2). Adding age and gender to the MANOVA
lowered the statistical significance of the GSH reduction (F=
4.28; p=0.042) and did not alter findings with any of the other
metabolites. There was no correlation between clinical ratings
and any of the metabolite levels (all p values, p>0.5), and
examination of the small number of melancholic depressed
patients separately also showed no difference from controls
(all p values, p>0.1). Six-week escitalopram treatment, which
resulted in clinical responses (50 % or greater decrease in
HAM-D) in 18 patients, did not alter concentrations of
GABA, glutamate, glutamine or GSH (Table 3). Similarly,
there was no correlation between change in HAM-D and
change in any metabolite level (all p values, p>0.1).
Discussion
The principal finding of our study is that, compared to con-
trols, depressed patients had lower levels of GSH in occipital
cortex. No significant change was seen in the other
neurometabolites measured, that is, GABA, glutamate and
Table 1 Demographic data for patient and control groups
Patients (n=33) Controls (n=27)
Gender, F/M 19:14 16:11





Data presented as mean±SD, and numbers of participants
HAM-D Hamilton Rating Scale for Depression, BDI Beck Depression
Inventory, STAI-T and STAI-S Spielberger’s State-Trait Anxiety Inventory
Fig. 1 Representative spectrum from the occipital cortex (OCC) along
with the LCModel fit and residual. The location of the region of interest is
also shown
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its precursor and metabolite glutamine. Further, we found that
6-week treatment with the SSRI, escitalopram, had no effect
on any of the metabolite levels, despite many of the patients
experiencing clinically significant improvements in depres-
sive symptomatology.
GSH is an important antioxidant in the CNS, and GSH
depletion is believed to contribute to various forms of cell
death (Bains and Shaw 1997). GSH has been relatively little
studied in MRS studies of depressed patients; nevertheless, as
noted in the “Introduction” section, peripheral measures of
antioxidant capacity in depression have shown reductions in
GPX, an enzyme whose role is to help protect the organism
from oxidative damage (Maes et al. 2011). A post-mortem
study in depressed patients also showed lowered levels of
GPX and GSH in cortex (Gawryluk et al. 2011). In agreement
with our findings, one previous MRS study found lowered
cortical GSH in relative to healthy controls in both patients
with major depression and patients with chronic fatigue syn-
drome (Shungu et al. 2012). While the latter study also
employed a voxel in occipital cortex, spectral acquisition
was carried out with point-resolved spectroscopy and J editing
(Shungu et al. 2012). However, two recent MRS studies in
bipolar disorder failed to find differences in cortical GSH
between bipolar patients and controls (Godlewska et al.
2014; Lagopoulos et al. 2013) suggesting that lowered GSH
is probably not a feature of mood disorders in general.
There is increasing interest in the role of glutamateric
mechanisms in depression, and MRS has been widely used
to measure glutamate in patients with mood disorder
(Sanacora et al. 2008). At conventional MR field strengths,
it is technically difficult to separate glutamate from glutamine,
and the two are often reported together as a composite mea-
sure called Glx. SPECIAL, however, does allow the differen-
tial resolution of glutamate and glutamine which were there-
fore measured separately in the current study (Mekle et al.
2009). However, no change between depressed patients and
controls was found in either metabolite or when the two were
summed together (data not shown).
The majority of MRS studies of Glx in depressed patients
have found lowered levels in anterior brain regions, though the
data are not completely consistent (Yüksel and Öngür 2010;
Price et al. 2009; Taylor et al. 2012). There is a piece of
evidence that lowered Glx may be more apparent in patients
with chronic depression (Portella et al. 2011), so altered gluta-
mate activity might be restricted to a subgroup with more
sustained and severe illness. Glx has been less studied in
occipital cortex, and one study in acutely depressed patients
Fig. 2 Individual GSH
concentrations referenced to
creatine in occipital cortex in
depressed patients and healthy
controls
Table 2 Comparisons of the voxel content and magnetic resonance
spectroscopy (MRS) measures relative to total creatine (mean±SD) for
glutathione, GABA, glutamate and glutamine, across both patients and
controls, corrected for grey matter content
Patients Healthy Significance value
Grey matter 0.38±00.072 0.421±0.070 (t(28)=2.191, p=0.033
White matter 0.510±0.056 0.490±0.053 (t(28)=−1.422, p=0.161
CSF 0.109±0.047 0.089±0.032 (t(28)=−1.912, p=0.061
GSH 0.174±0.013 0.183±0.014 F=5.098, p=0.028
GABA 0.225±0.034 0.237±0.053 F=0.507, p=0.33
Glutamate 0.890±0.085 0.880±0.090 F=0.001, p=0.97
Glutamine 0.192±0.036 0.187±0.030 F=0.008, p=0.93
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reported an increase in glutamate (Sanacora et al. 2004); we
also found increased Glx in occipital cortex in recovered
depressed patients (Bhagwagar et al. 2007) and increased
glutamate in the same brain region in euthymic young people
at risk of depression through having a depressed parent
(Taylor et al. 2011). More recently, we have also found ele-
vated levels of Glx in the hippocampus in young people at
increased risk of depression (Mannie et al. 2014).
Our current finding of unaltered Glx in occipital cortex in
acute depression is in agreement with a recent study that found
no difference in occipital Glx between depressed patients,
patients with chronic fatigue and controls (Murrough et al.
2010), as well as an earlier investigation that included both
medication-naive and medication-resistant depressed patients
(Price et al. 2009). These disparate findings make it hard to
form a coherent picture of MRS glutamate abnormalities in
depressed patients. It is possible that stage of illness might be
important with ‘at-risk’ individuals showing increased Glx
levels followed by a decline over the course of recurrent
episodes of depression (de Diego-Adeliño et al. 2013).
Changes may also depend on the brain region studied
(Taylor et al. 2010).
GABA concentration has also been reported to be lower in
MRS studies in depression, in both anterior brain regions and in
occipital cortex, though again not all studies are in agreement
(Sanacora et al. 1999, 2004; Hasler et al. 2007; Walter et al.
2009;Murrough et al. 2010). A previous investigation in a large
group of unmedicated depressed patients found that levels of
GABA in occipital cortex weremarkedly lower than controls in
patients with melancholic depression but reduced to lesser
extent in those with non-melancholic forms of illness
(Sanacora et al. 2004). Thus, severity, or the particular symp-
tom profile associated with melancholic depression, might be
more clearly associated with lowered GABA levels as mea-
sured by MRS. Perhaps relevant to this is the study of Price
et al. (2009) which found diminished GABA levels in both
anterior cingulate cortex and occipital cortex in depressed
patients who had been refractory to at least three courses of
antidepressant treatment during their current episode of illness.
However, other depressed patients, either treatment-naive or
with lesser degrees of treatment resistance did not show lower
GABA levels in either brain region. We therefore also analysed
our GABA data by comparing the GABA levels of patients
who failed to show a clinical response to escitalopram treatment
over the next 6 weeks with those who showed at least a 50 %
decrease in HAM-D but found no difference in pre-treatment
(baseline) GABA levels between responders and non-
responders (data not shown). However, the treatment resis-
tance of these patients was clearly less than those studied by
Price et al. (2009).
We found no significant effect of 6-week treatment with
escitalopram on any of the neurometabolites that we studied.
There is little work on the effects of sub-chronic antidepres-
sant treatment on Glx concentrations in MR studies of de-
pressed patients, though our findings are in agreement with
previous work from our group that studied the effect of 1-
week treatment with escitalopram in depressed patients
(Taylor et al. 2012). There is, however, a previous report that
SSRIs increase occipital GABA levels in depressed patients
over about 2 months of treatment (Sanacora et al. 2002), and a
similar effect was reported with electroconvulsive therapy
(Sanacora et al. 2003). In the latter studies, however, GABA
levels were lowered relative to controls prior to the treatment
interventions, perhaps making an increase easier to
demonstrate.
We used a novel form of spectral acquisition (SPECIAL)
which employed short echo times to allow identification of
several neurometabolites without the need for spectral editing
(Mekle et al. 2009). It is possible therefore that the lack of
differences we have found between depressed patients and
controls in concentrations of glutamate and GABA could be
attributable to the particular MRS technique that we applied.
For example, edited MRS measures of GABA are known to
contain contaminating signals from macromolecules, whereas
the macromolecule contribution to short echo time GABA
measures is not well known. Nonetheless, we have previously
shown that there is a highly significant correlation between
occipital GABA levels measured with SPECIAL and a more
conventional spectral editing technique (Near et al. 2013).
Unexpectedly, we found that compared to controls, the de-
pressed patients had a lower grey matter content in the occip-
ital voxel selected for MRS study. While some investigations
have found decreases in grey matter in certain brain regions in
depression, the occipital cortex is not usually implicated
(Kupfer et al. 2012). In fact, in the present study, we have also
compared overall brain structure between the depressed pa-
tients and controls using voxel-based morphometry and found
no significant differences (data not shown). We therefore
believe that the decrease in grey matter in the occipital voxel
in the depressed patients is likely to be a chance finding.
Another potential limitation of our study is the use of
creatine as a reference because it is possible that certain
psychiatric disorders might be associated with changes in
brain creatine levels (Öngür et al. 2009). We think this is
Table 3 Magnetic resonance spectroscopy (MRS) measures relative to
total creatine (mean±SD) for glutathione, GABA, glutamate and glutamine







GSH 0.174±0.012 0.177±0.014 0.28
GABA 0.226±0.032 0.221±0.035 0.52
Glutamate 0.893±0.086 0.865±0.088 0.08
Glutamine 0.188±0.036 0.188±0.039 0.99
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unlikely because an abnormality in creatine levels would be
expected to lead to more widespread differences in metabolite
ratios between patients and controls; however, it would have
been preferable to use a method capable of measuring absolute
concentrations of the metabolites of interest. Finally, the use of
occipital cortex may have limited relevance to understanding
biochemistry of depression because functional imaging in
depression typically shows changes in anterior brain regions
involved in emotional regulation (Kupfer et al. 2012).
In conclusion, our studies indicate that GSH levels may be
decreased in patients with major depression, supporting a pre-
vious MRS investigation in depression as well as theoretical
approaches that implicate impaired antioxidant mechanisms in
the pathophysiology of mood disorder. However, in our patient
group, we did not find evidence of decreases in cortical Glx and
GABA as has been reported by many other studies. It is
important to understand the reason for the discrepant MRS
findings in depressed patients, and our study suggests that
concomitant treatment with SSRIs may not be an important
confounding factor. It seems more likely that patient heteroge-
neity plays an important role, and in this context, it seemsworth
noting that our patients, in general, were not severely de-
pressed, nor treatment resistant. In future work, it will be
important to identify the clinical characteristics that are most
reliably associated with alterations in cortical Glx and GABA.
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